Literature DB >> 27931131

Baseline and treatment-related changes in thrombin generation in patients with multiple myeloma.

Ing S Tiong1,2, Susan E Rodgers1,3, Cindy H S Lee1,2,4, Simon J McRae1,3,4.   

Abstract

The prothrombotic risk in multiple myeloma (MM) could be potentially assessed by thrombin generation (TG) assays. TG was performed using Calibrated Automated Thrombography with 5 and 1 pM tissue factor. We compared baseline TG among 24 MM patients, 19 MGUS, and 50 healthy controls, and assessed change in TG in MM patients during the initial treatment period at 1, 2, and 3 months. MM subjects demonstrated increased FVIII and VWF:Ag levels pretreatment, and a prothrombotic TG phenotype with increased velocity index, reduced lag time and time-to-peak, and increased resistance to thrombomodulin inhibition. There were no significant changes in TG with treatment for the majority of parameters, however, MM subjects exhibited persistent elevation of velocity index throughout treatment. Two subjects developed thrombosis during the study period despite thromboprophylaxis. This study provides information on the optimal conditions for examining TG as a predictor of thrombotic risk in MM patients.

Entities:  

Keywords:  Monoclonal gammopathy; hypercoagulability; multiple myeloma; thrombin generation; venous thromboembolism

Mesh:

Substances:

Year:  2016        PMID: 27931131     DOI: 10.1080/10428194.2016.1219900

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  6 in total

Review 1.  Global coagulation assays in hypercoagulable states.

Authors:  Hui Yin Lim; Geoffrey Donnan; Harshal Nandurkar; Prahlad Ho
Journal:  J Thromb Thrombolysis       Date:  2022-01-08       Impact factor: 2.300

2.  Patients With Multiple Myeloma Have a Disbalanced Whole Blood Thrombin Generation Profile.

Authors:  Li Li; Mark Roest; Yaqiu Sang; Jasper A Remijn; Rob Fijnheer; Karel Smit; Dana Huskens; Jun Wan; Bas de Laat; Joke Konings
Journal:  Front Cardiovasc Med       Date:  2022-06-27

3.  Incidence of Venous Thromboembolism in Multiple Myeloma Patients across Different Regimens: Role of Procoagulant Microparticles and Cytokine Release.

Authors:  Antonio Gidaro; Roberto Manetti; Alessandro Palmerio Delitala; Mark Johns Soloski; Giorgio Lambertenghi Deliliers; Dante Castro; Davide Soldini; Roberto Castelli
Journal:  J Clin Med       Date:  2022-05-11       Impact factor: 4.964

4.  Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis.

Authors:  Maxime G Zermatten; Montserrat Fraga; Debora Bertaggia Calderara; Alessandro Aliotta; Darius Moradpour; Lorenzo Alberio
Journal:  JHEP Rep       Date:  2020-05-11

5.  Thrombin generation in newly diagnosed multiple myeloma during the first three cycles of treatment: An observational cohort study.

Authors:  Emilie Chalayer; Brigitte Tardy-Poncet; Lionel Karlin; Céline Chapelle; Aurélie Montmartin; Michèle Piot; Denis Guyotat; Philippe Collet; Thomas Lecompte; Bernard Tardy
Journal:  Res Pract Thromb Haemost       Date:  2018-12-13

6.  Analysis of Coagulation Abnormality in Patients with Multiple Myeloma and Its Clinical Significance.

Authors:  Pengji Pan; Junxia Liu
Journal:  Evid Based Complement Alternat Med       Date:  2022-06-20       Impact factor: 2.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.